nach oben

European Journal of Nuclear Medicine and Molecular Imaging

Erschienen in:

08.12.2021 | COVID-19 | Original Article Zur Zeit gratis

The impact of the COVID-19 pandemic on oncological disease extent at FDG PET/CT staging: the ONCOVIPET study

verfasst von: Carmelo Caldarella, Fabrizio Cocciolillo, Silvia Taralli, Margherita Lorusso, Valentina Scolozzi, Daniele Antonio Pizzuto, Maria Lucia Calcagni, Vittoria Rufini, Davide Guido, Fernando Palluzzi, Luciano Giacò, Alessandro Giordano, Lucia Leccisotti

Erschienen in: European Journal of Nuclear Medicine and Molecular Imaging | Ausgabe 5/2022

Einloggen, um Zugang zu erhalten

Abstract

Purpose

To investigate whether the COVID-19 pandemic and national lockdown had an impact on the extent of cancer disease at FDG PET/CT staging as surrogate marker.

Methods

Retrospective observational study including cancer patients submitted to FDG PET/CT staging from June 1 to October 31, 2020, and June 1 to October 31, 2019, respectively. Data regarding primary tumour, nodal (N) status and number of involved nodal stations, and presence and number of distant metastases (M) were collected. Each scan was classified in limited vs advanced status. Data were aggregated across the study population and tumour type. Bi-weekly frequencies of the observed events were analysed.

Results

Six hundred eleven patients were included (240 in 2019 vs 371 in 2020, respectively). A significant increase of advanced disease patients (rate 1.56, P < 0.001), N + or M + patients (rate 1.84 and 2.09, respectively, P < 0.001), and patients with a greater number of involved N stations or M (rate 2.01 and 2.06, respectively, P < 0.001) were found in 2020 compared with data of 2019. Analysis by tumour type showed a significant increase of advanced disease in lymphoma and lung cancer in 2020 compared with 2019 (P < 0.001). In addition, a significant increase of nodal involvement was found in lung, gastro-intestinal, and breast cancers, as well as in lymphoma patients (P < 0.02). A significant increase of distant metastases was found in lung cancers (P = 0.002).

Conclusion

Cancer patients with advanced disease at FDG PET/CT staging increased in 2020 compared with 2019, following the national lockdown due to the COVID-19 pandemic, 1.5-fold with a significant increase of patients with N or M involvement. Targeted health interventions are needed to mitigate the effects of the pandemic on patient outcome.

Nur mit Berechtigung zugänglich

Patt D, Gordan L, Diaz M, Okon T, Grady L, Harmison M, et al. Impact of COVID-19 on cancer care: how the pandemic is delaying cancer diagnosis and treatment for American seniors. JCO Clin Cancer Inform. 2020;4:1059–71. https://doi.org/10.1200/CCI.20.00134.CrossRefPubMed

de Jonge L, Worthington J, van Wifferen F, Iragorri N, Peterse EFP, Lew JB, et al. Impact of the COVID-19 pandemic on faecal immunochemical test-based colorectal cancer screening programmes in Australia, Canada, and the Netherlands: a comparative modelling study. Lancet Gastroenterol Hepatol. 2021. https://doi.org/10.1016/S2468-1253(21)00003-0.CrossRefPubMed

Oderda M, Calleris G, Falcone M, Fasolis G, Muto G, Oderda G, et al. How uro-oncology has been affected by COVID-19 emergency? Data from Piedmont/Valle d’Aosta Oncological Network. Ital Urol. 2021;88:3–8. https://doi.org/10.1177/0391560320946186.CrossRef

Fabi A, Pugliese P, Falbo PT, Corsi D, Fabbri MA, Vincenzi B, et al. The experience of oncology healthcare providers in the Central Italy during the COVID-19 lockdown. Cancers (Basel). 2020;12:3031. https://doi.org/10.3390/cancers12103031.CrossRefPubMedCentral

Quaquarini E, Saltalamacchia G, Presti D, Caldana G, Tibollo V, Malovini A, et al. Impact of COVID-19 outbreak on cancer patient care and treatment: data from an outpatient oncology clinic in Lombardy (Italy). Cancers (Basel). 2020;12:2941. https://doi.org/10.3390/cancers12102941.CrossRef

Hirschfeld CB, Shaw LJ, Williams MC, Lahey R, Villines TC, Dorbala S, et al. Impact of COVID-19 on cardiovascular testing in the United States versus the rest of the world: The INCAPS-COVID Study. JACC Cardiovasc Imaging. 2021. https://doi.org/10.1016/j.jcmg.2021.03.007.CrossRefPubMedPubMedCentral

Saini KS, de Las HB, de Castro J, Venkitaraman R, Poelman M, Srinivasan G, et al. Effect of the COVID-19 pandemic on cancer treatment and research. Lancet Haematol. 2020;7:e432–5. https://doi.org/10.1016/S2352-3026(20)30123-X.CrossRefPubMedPubMedCentral

Di Bidino R, Cicchetti A. Impact of SARS-CoV-2 on provided healthcare. Evidence From the Emergency Phase in Italy. Front Public Health. 2020;8:583583. https://doi.org/10.3389/fpubh.2020.583583.CrossRefPubMedPubMedCentral

Torzilli G, Viganò L, Galvanin J, Castoro C, Quagliuolo V, Spinelli A, et al. A snapshot of elective oncological surgery in Italy during COVID-19 emergency: pearls, pitfalls, and perspectives. Ann Surg. 2020;272:e112–7. https://doi.org/10.1097/SLA.0000000000004081.CrossRefPubMed

10.

Albano D, Bruno A, Bruno F, Calandri M, Caruso D, Clemente A, et al. Impact of coronavirus disease 2019 (COVID-19) emergency on Italian radiologists: a national survey. Eur Radiol. 2020;30:6635–44. https://doi.org/10.1007/s00330-020-07046-7.CrossRefPubMedPubMedCentral

11.

Onesti CE, Tagliamento M, Curigliano G, Harbeck N, Bartsch R, Wildiers H, et al. Expected medium- and long-term impact of the COVID-19 outbreak in oncology. JCO Glob Oncol. 2021;7:162–72. https://doi.org/10.1200/GO.20.00589.CrossRefPubMed

12.

Boellaard R, Delgado-Bolton R, Oyen WJ, Giammarile F, Tatsch K, Eschner W, et al. FDG PET/CT: EANM procedure guidelines for tumour imaging: version 2.0. Eur J Nucl Med Mol Imaging. 2015;42(328):54. https://doi.org/10.1007/s00259-014-2961-x.CrossRef

13.

Kostakoglu L, Agress H, Goldsmith SJ. Clinical role of FDG PET in evaluation of cancer patients. Radiographics. 2003;23:315–40. https://doi.org/10.1148/rg.232025705 (quiz 533).CrossRef

14.

Kandathil A, Kay FU, Butt YM, Wachsmann JW, Subramaniam RM. Role of FDG PET/CT in the Eighth Edition of TNM Staging of Non small Cell Lung Cancer. Radiographics. 2018;38:2134–49. https://doi.org/10.1148/rg.2018180060.CrossRefPubMed

15.

Wartski M, Sauvanet A. 18F-FDG PET/CT in pancreatic adenocarcinoma: a role at initial imaging staging? Diagn Interv Imaging. 2019;100:735–41. https://doi.org/10.1016/j.diii.2019.07.006.CrossRefPubMed

16.

Paydary K, Seraj SM, Zadeh MZ, Emamzadehfard S, Shamchi SP, Gholami S, et al. The evolving role of FDG-PET/CT in the diagnosis, staging, and treatment of breast cancer. Mol Imaging Biol. 2019;21:1–10. https://doi.org/10.1007/s11307-018-1181-3.CrossRefPubMed

17.

Ha HK, Koo PJ, Kim SJ. Diagnostic accuracy of F-18 FDG PET/CT for preoperative lymph node staging in newly diagnosed bladder cancer patients: a systematic review and meta-analysis. Oncology. 2018;95:31–8. https://doi.org/10.1159/000488200.CrossRefPubMed

18.

CaresiaAroztegui AP, García Vicente AM, Alvarez Ruiz S, Delgado Bolton RC, Orcajo Rincon J, Garcia Garzon JR, et al. 18F-FDG PET/CT in breast cancer: evidence-based recommendations in initial staging. Tumour Biol. 2017;39:1010428317728285. https://doi.org/10.1177/1010428317728285.CrossRef

19.

Thanarajasingam G, Bennani-Baiti N, Thompson CA. PET-CT in staging, response evaluation, and surveillance of lymphoma. Curr Treat Options Oncol. 2016;17:24. https://doi.org/10.1007/s11864-016-0399-z.CrossRefPubMed

20.

Perng P, Marcus C, Subramaniam RM. (18)F-FDG PET/CT and melanoma: staging, immune modulation and mutation-targeted therapy assessment, and prognosis. AJR Am J Roentgenol. 2015;205:259–70. https://doi.org/10.2214/AJR.14.13575.CrossRefPubMed

21.

Jones M, Hruby G, Solomon M, Rutherford N, Martin J. The role of FDG-PET in the initial staging and response assessment of anal cancer: a systematic review and meta-analysis. Ann Surg Oncol. 2015;22:3574–81. https://doi.org/10.1245/s10434-015-4391-9.CrossRefPubMed

22.

Kaneko Y, Murray WK, Link E, Hicks RJ, Duong C. Improving patient selection for 18F-FDG PET scanning in the staging of gastric cancer. J Nucl Med. 2015;56:523–9. https://doi.org/10.2967/jnumed.114.150946.CrossRefPubMed

23.

Mak D, Corry J, Lau E, Rischin D, Hicks RJ. Role of FDG-PET/CT in staging and follow-up of head and neck squamous cell carcinoma. Q J Nucl Med Mol Imaging. 2011;55:487–99.PubMed

24.

Yousefi-Koma A, Panah-Moghaddam M, Kalff V. The utility of metabolic imaging by 18F-FDG PET/CT in lung cancer: impact on diagnosis and staging. Tanaffos. 2013;12:16–25.PubMedPubMedCentral

25.

Amin MB, Edge SB, Greene FL, Byrd DR, Brookland RK, Washington MK, Gershenwald JE, Compton CC, Hess KR, Sullivan DC, Jessup JM, Brierley JD, Gaspar LE, Schilsky RL, Balch CM, Winchester DP, Asare EA, Madera M, Gress DM, Meyer LR (editors). AJCC cancer staging manual. 8th ed. Springer International Publishing; 2017.

26.

Wang X. Firth logistic regression for rare variant association tests. Front Genet. 2014;5:187. https://doi.org/10.3389/fgene.2014.00187.CrossRefPubMedPubMedCentral

27.

Jereczek-Fossa BA, Pepa M, Marvaso G, Bruni A, Buglione di Monale E, Bastia M, Catalano G, et al. COVID-19 outbreak and cancer radiotherapy disruption in Italy: survey endorsed by the Italian Association of Radiotherapy and Clinical Oncology (AIRO). Radiother Oncol. 2020;149:89–93. https://doi.org/10.1016/j.radonc.2020.04.061.CrossRefPubMedPubMedCentral

28.

Oldani C, Vanni G, Buonomo OC. COVID-19 unintended effects on breast cancer in Italy after the great lockdown. Front Public Health. 2020;8: 601748. https://doi.org/10.3389/fpubh.2020.601748.CrossRefPubMedPubMedCentral

29.

Fortunato L, d’Amati G, Taffurelli M, Tinterri C, Marotti L, Cataliotti L. Severe impact of Covid-19 pandemic on breast cancer care in Italy: a Senonetwork national survey. Clin Breast Cancer. 2020. https://doi.org/10.1016/j.clbc.2020.10.012.CrossRefPubMed

30.

Rebecchi F, Arolfo S, Ugliono E, Morino M, Asti E, Bonavina L, et al. Impact of COVID-19 outbreak on esophageal cancer surgery in Northern Italy: lessons learned from a multicentric snapshot. Dis Esophagus. 2020. https://doi.org/10.1093/dote/doaa124.CrossRef

31.

Lambertini M, Toss A, Passaro A, Criscitiello C, Cremolini C, Cardone C, Cancer care during the spread of coronavirus disease, et al. (COVID-19) in Italy: young oncologists’ perspective. ESMO Open. 2019;2020:5. https://doi.org/10.1136/esmoopen-2020-000759.CrossRef

32.

https://www.agenas.gov.it/covid19/web/index.php?r=site%2Fresilienza. 2021.

33.

Hanna TP, King WD, Thibodeau S, Jalink M, Paulin GA, Harvey-Jones E, et al. Mortality due to cancer treatment delay: systematic review and meta-analysis. BMJ. 2020;371: m4087. https://doi.org/10.1136/bmj.m4087.CrossRefPubMed

34.

Gheorghe A, Maringe C, Spice J, Purushotham A, Chalkidou K, Rachet B, et al. Economic impact of avoidable cancer deaths caused by diagnostic delay during the COVID-19 pandemic: a national population-based modelling study in England. UK Eur J Cancer. 2021. https://doi.org/10.1016/j.ejca.2021.04.019.CrossRefPubMed

35.

Maringe C, Spicer J, Morris M, Purushotham A, Nolte E, Sullivan R, et al. The impact of the COVID-19 pandemic on cancer deaths due to delays in diagnosis in England, UK: a national, population-based, modelling study. Lancet Oncol. 2020;21:1023–34. https://doi.org/10.1016/S1470-2045(20)30388-0.CrossRefPubMedPubMedCentral

36.

Sud A, Torr B, Jones ME, Broggio J, Scott S, Loveday C, et al. Effect of delays in the 2-week-wait cancer referral pathway during the COVID-19 pandemic on cancer survival in the UK: a modelling study. Lancet Oncol. 2020;21:1035–44. https://doi.org/10.1016/S1470-2045(20)30392-2.CrossRefPubMedPubMedCentral

37.

Higashi K, Ueda Y, Ayabe K, Sakurai A, Seki H, Nambu Y, et al. FDG PET in the evaluation of the aggressiveness of pulmonary adenocarcinoma: correlation with histopathological features. Nucl Med Commun. 2000;21:707–14. https://doi.org/10.1097/00006231-200008000-00002.CrossRefPubMed

Titel: The impact of the COVID-19 pandemic on oncological disease extent at FDG PET/CT staging: the ONCOVIPET study
verfasst von: Carmelo Caldarella
Fabrizio Cocciolillo
Silvia Taralli
Margherita Lorusso
Valentina Scolozzi
Daniele Antonio Pizzuto
Maria Lucia Calcagni
Vittoria Rufini
Davide Guido
Fernando Palluzzi
Luciano Giacò
Alessandro Giordano
Lucia Leccisotti
Publikationsdatum: 08.12.2021
Verlag: Springer Berlin Heidelberg
Schlagwort: COVID-19
Erschienen in: European Journal of Nuclear Medicine and Molecular Imaging / Ausgabe 5/2022
Print ISSN: 1619-7070
Elektronische ISSN: 1619-7089
DOI: https://doi.org/10.1007/s00259-021-05629-0

Die Highlights vom Kongress des American College of Cardiology 2024

Springer Medizin

The impact of the COVID-19 pandemic on oncological disease extent at FDG PET/CT staging: the ONCOVIPET study

Abstract

Purpose

Methods

Results

Conclusion

Die Highlights vom Kongress des American College of Cardiology 2024

Springer Medizin

Abstract

Purpose

Methods

Results

Conclusion

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 5/2022

Incidence rate and factors associated with the development of secondary cancers after radioiodine therapy in differentiated thyroid cancer: a multicenter retrospective study

Efficacy and safety of 225Ac-DOTATATE targeted alpha therapy in metastatic paragangliomas: a pilot study

EANM procedure guideline for the treatment of liver cancer and liver metastases with intra-arterial radioactive compounds

Prospective analysis of clinically significant prostate cancer detection with [18F]DCFPyL PET/MRI compared to multiparametric MRI: a comparison with the histopathology in the radical prostatectomy specimen, the ProStaPET study

High-resolution pediatric age–specific 18F-FDG PET template: a pilot study in epileptogenic focus localization

Phase I/II clinical trial of high-dose [131I] meta-iodobenzylguanidine therapy for high-risk neuroblastoma preceding single myeloablative chemotherapy and haematopoietic stem cell transplantation